iBio logo

iBioNYSE American: IBIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 August 2008

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$23.06 M
-88%vs. 3y high
26%vs. sector
-vs. 3y high
-vs. sector
-45%vs. 3y high
43%vs. sector
102.50
-48%vs. 3y high
94%vs. sector

Price

regular market | Mon, 04 Nov 2024 14:30:00 GMT
$2.67+$0.10(+3.89%)

Dividend

No data over the past 3 years
$175.00 K-$7.78 M

Analysts recommendations

Institutional Ownership

IBIO Latest News

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
globenewswire.com20 September 2024 Sentiment: POSITIVE

SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.

3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
InvestorPlace05 April 2024 Sentiment: NEGATIVE

The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience a surge in stock price, the healthcare industry also has many stocks that plummet.

iBio stock nearly tripled on Wednesday: here's why
Invezz27 March 2024 Sentiment: POSITIVE

Shares of iBio Inc (NYSEAMERICAN: IBIO) close to tripled on Wednesday after the biotechnology company announced a collaboration with AstralBio Inc.

iBio partners with AstralBio to develop obesity treatments using AI-driven platform
Proactive Investors27 March 2024 Sentiment: POSITIVE

iBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions. The company said the collaboration brings together its ability to create antibodies against hard-to-drug targets using its patented Generative AI and machine learning platform with AstralBio's experience in biologics and drug development.

Why Is iBio (IBIO) Stock Up 125% Today?
InvestorPlace27 March 2024 Sentiment: POSITIVE

iBio‘s (NYSEMKT: IBIO ) shares are trending, and IBIO stock is up 125% today after the firm used two of the market's favorite buzzwords — artificial intelligence (AI) and obesity drugs — in a press release that unveiled a new initiative. Specifically, the firm announced that its AI drug discovery platform would be used to develop obesity treatments.

Why Is iBio (IBIO) Stock Down 41% Today?
InvestorPlace05 December 2023 Sentiment: NEGATIVE

Ibio (NYSEMKT: IBIO ) stock is falling hard on Tuesday after the biotechnology company announced the pricing of a public share offering. That offering has the company selling 2.25 million shares of IBIO stock for $2 each.

Why Is iBio (IBIO) Stock Up 16% Today?
InvestorPlace13 June 2023 Sentiment: POSITIVE

Ibio (NYSEMKT: IBIO ) stock is rising higher on Tuesday as investors react to the company reaching a research collaboration agreement with the NIH. This will see the company teaming up with the NIH's National Institute of Allergy and Infectious Diseases (NIAID).

What type of business is iBio?

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

What sector is iBio in?

iBio is in the Healthcare sector

What industry is iBio in?

iBio is in the Biotechnology industry

What country is iBio from?

iBio is headquartered in United States

When did iBio go public?

iBio initial public offering (IPO) was on 19 August 2008

What is iBio website?

https://ibioinc.com

Is iBio in the S&P 500?

No, iBio is not included in the S&P 500 index

Is iBio in the NASDAQ 100?

No, iBio is not included in the NASDAQ 100 index

Is iBio in the Dow Jones?

No, iBio is not included in the Dow Jones index

When was iBio the previous earnings report?

No data

When does iBio earnings report?

The next expected earnings date for iBio is 14 November 2024